Skip to main content

IMCD Indonesia strengthens its life science portfolio with the acquisition of PT Megasetia Agung Kimia

Written by Customer Service on . Posted in Mergers And Acquisitions.

Photo – IMCD Indonesia strengthens its life science portfolio with the acquisition of PT Megasetia Agung Kimia

In the picture, Adelia Sia, Managing Director of IMCD Indonesia (left), and Suryani Hartoyo, President Director of Megasetia (right).

In the picture, Adelia Sia, Managing Director of IMCD Indonesia (left), and Suryani Hartoyo, President Director of Megasetia (right).

ROTTERDAM, The Netherlands (17 November 2021) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Indonesia has signed an agreement to acquire 100% of the shares of PT Megasetia Agung Kimia (“Megasetia”) in Indonesia. Megasetia is an excellent fit with IMCD’s life science strategy and provides a significant platform for further growth in the life science segments in Indonesia.

The transaction will take place in two tranches, with IMCD now acquiring 70% of Megasetia’s share capital and the remaining 30% in 2025. The management of Megasetia will continue to lead the company post completion of the first tranche.

Founded in 1995, Megasetia is the leading distributor of speciality ingredients for the pharmaceuticals industry in Indonesia. In addition, it covers the personal care, home care, animal health, and industrial markets, offering end-to-end solutions to its customers and partners with 3 laboratories, 6 offices, and 6 warehouses across Indonesia. Megasetia generated a revenue of approximately IDR 974 billion (ca. EUR 60 million) in 2020 with around 160 employees. It currently serves more than 1,000 customers and represents over 50 of the world’s leading ingredients producers.

“Indonesia is South East Asia’s largest economy and this acquisition provides excellent growth opportunities to strengthen IMCD’s positioning in the life science segments. In addition, it enables us to enhance our offering to local customers and partners,” said Haiko Zuidhoff, Vice President of IMCD APAC.

“We are delighted to be part of IMCD’s global network. We are confident that our life science portfolio will complement their offering to customers and suppliers,” commented Suryani Hartoyo, President Director of Megasetia. “Our culture of growth through market knowledge, technical innovation, and high level of services, is very well aligned with IMCD’s strategy,” concluded Hartoyo.

The closing of the transaction is expected to take place in December 2021.

Attached, please find a pdf format of the press release, the main picture, and its caption.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.